Bellevue, WA – According to filings with the U.S. Securities and Exchange Commission, Viome Life Sciences is raising $67,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Naveen Jain played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Viome Life Sciences
Viome Life Sciences was founded in 2016 with a mission to make illness optional by predicting and preventing chronic diseases, cancers, and aging through a deeper understanding of an individuals biology at a molecular level. Viomes Consumer Services (VIOME) provides the industry’s only direct-to-consumer healthcare test that analyzes microbial and human gene expressions (mRNA), with technology exclusively licensed from Los Alamos National Lab, in order to provide individuals with health insights and the nutrition they need. Our Health Sciences division focuses on key initiatives including prediction, early diagnostics, prognostics, and precision therapeutics to help people live a disease free life. With our state of the art artificial intelligence platform, we are able to analyze data from the worlds largest and richest gene expression database in order to identify the root causes of chronic diseases, cancers, and aging and the mechanisms of action to be able to prevent and reverse them. Prediction: Using advanced AI methods to discover host/microbial biomarkers that predict the risk of developing severe chronic conditions, including cancers. Early Diagnostics: Using host/microbial biomarkers to diagnose severe chronic conditions including cancers at the earliest possible stage. Early diagnosis will enable earlier treatment which often is associated with higher efficacy. Prognostics: Leveraging host/microbial biomarkers to develop companion diagnostics to predict drug effectiveness and further improve responsiveness of patients by proposing AI-guided modulation of the microbiome. Therapeutics: By targeting the root cause of specific chronic diseases with prophylactics or therapeutics such as drugs, monoclonal antibodies, vaccines, phages, or other appropriate modalities.

To learn more about Viome Life Sciences, visit http://www.viomelifesciences.com/

Contact:
Naveen Jain, Chief Executive Officer
425-830-6556
https://www.linkedin.com/in/naveenjainintelius/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved